Open Access

Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey


Cite

Second liquid biopsy results in adenocarcinoma and non-small cell lung cancer-not otherwise specified patients.

# First Liquid Biopsy Second Liquid Biopsy Prior Treatment
2 EGFR exon 19 A750P; EGFR exon 19 L747_E749del no variant detected erlotinib
10 EGFR exon 18 G721V no variant detected paclitaxel + carboplatin
13 no variant detected no variant detected paclitaxel + carboplatin
15 EGFR exon 21 L858R BRAF exon 15 R603* erlotinib
31 ERBB2 amplification no variant detected paclitaxel + carboplatin
38 EGFR exon 19 E746_A750del no variant detected erlotinib
55 EGFR exon 19 E746_A750del EGFR exon 19 E746_A750del; EGFR exon 20 T790M erlotinib
95 ALK exon 22 C1156S no variant detected crizotinib

General demographics and histology.

General Demographics n Histology n
Patients 100 SCC 14
Median age (range) 59.3 (26-79) AC 73
Males/Females 80/20 NSCLC-NOS 13

Detailed Molecular Findings of Adenocarcinoma and NSLC-NOS patients with detectable EGFR mutations

Patient Number Activating Mutation(s) Resistance Mutation(s) Polymorphism
2 EGFR Exon 19 A750P, EGFR Exon 19 L747_E749 del
4 EGFR Exon 19
6 EGFR Exon 21 L858R EGFR Exon 20 T790M
7 EGFR Exon 20 C797S EGFR Exon 21 L858R EGFR Exon 20 T790M
10 EGFR Exon 18 G721V
12 EGFR Exon 20 S768I EGFR Exon 21 L858R
15 EGFR Exon 21 L858R
33 KRAS Exon 2 G12C EGFR Exon 13 R521K
38 EGFR Exon 19 E746_A750del
39 EGFR Exon 18 G721S
40 EGFR Exon 20 S784T
41 EGFR Exon 19 P753P
48 EGFR Exon 19 T751_E758del
50 EGFR Exon 19 L747_P753delinsS
53 EGFR Exon 20 A767_V469 duplication ERBB2 amplification
55 EGFR Exon 19 E746_A750del
57 EGFR Exon 19 E746_T751delinsA
63 EGFR Exon 20 T790M EGFR Exon 20 C797S
69 EGFR Exon 18 I706S
73 EGFR Exon 20 H773fs *53, Met amplification
78 EGFR Exon 20 K806I, Met Exon 14 R988H, Met Exon 14 Y989C
80 KRAS Exon 2 G12C EGFR Exon 13 R521K
81 EGFR Exon 20 D807fs *90
84 EGFR Exon 20 V786L
85 EGFR Exon 21 A864T
86 EGFR Exon 19 L747_T751del KRAS Exon 2 G12S, Met Exon 14 E1012K
88 EGFR Exon 19 E746_A750delELRE A, EGFR Amplification

Detailed molecular findings of adenocarcinoma and non-small cell lung cancer-not otherwise specified patients other than EGFR mutations.

# Activating Mutation(s) Resistance Mutation(s) Polymorphism
5 KRAS exon 2 G12C
33 KRAS exon 2 G12C EGFR exon 13 R521K
37 KRAS exon 2 G12V
49 KRAS exon 2 G12V (c.35G>T)
80 KRAS exon 2 G12C EGFR exon 13 R521K
86 EGFR exon 19 L747_T751del; MET exon 14 E1012K KRAS exon 2 G12S
87 KRAS exon 2 G12D
90 KRAS intron 2
14 MET amplification
73 EGFR exon 20 H773fs*53; MET amplification
78 EGFR exon 20 K806I; MET exon 14 R988H; MET exon 14 Y989C
44 ALK exon 29 K1491R ERBB2 exon 17 I655V EGFR exon 13 R521K
95 ALK exon 22 C1156S
31 ERBB2 amplification
53 EGFR exon 20 A767_V469dup; ERBB2 amplification
79 ERBB2 exon 17 I655V
58 PDGFRA c.236G>A (G79D); KIT c.2362-77G>A
18 BRAF exon 11 G469E

Targetable mutations in squamous cell carcinoma patients.

n Activating Mutation(s) Resistance Mutation
24 MET exon 14 I491T
29 MET exon 14 V1014V
56 EGFR exon 21 L858R EGFR exon 20 T790M
eISSN:
1311-0160
Language:
English
Publication timeframe:
2 times per year
Journal Subjects:
Medicine, Basic Medical Science, other